Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
67.95 USD   +3.80%
08/09Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $52 from $49, Updates Model with Q2 Actuals; Keeps Neutral Rating
08/09Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $113 From $102, Reiterates Strong Buy Rating
08/09Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $102 From $91, Reiterates Buy Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

07/07/2021 | 10:07pm EDT

WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis approximately $198.6 million in aggregate principal amount of Notes held by them for (i) 4,530,431 shares of Apellis’ common stock, which is equal to 22.8065 shares per $1,000 principal amount of Notes exchanged plus (ii) an additional number of shares of Apellis’ common stock per $1,000 principal amount of Notes exchanged equal to the quotient of (a) $449.64 divided by (b) the average of the daily volume-weighted average prices of Apellis’ common stock over the 10 consecutive trading days commencing on July 8, 2021. The exchange transactions are expected to close on July 23, 2021, subject to the satisfaction of customary closing conditions.

The shares of Apellis’ common stock issuable in the exchanges have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and such other jurisdictions.

This press release does not constitute an offer to sell or a solicitation to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the closing of the exchanges will be satisfied and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 28, 2021 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Tracy Vineis
+1 617 420 4839

Investor Contact:
Argot Partners
+1 212.600.1902

Primary Logo

© GlobeNewswire 2021
08/09Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $52 from $49, Updates Mod..
08/09Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $113 From $102, Reiter..
08/09Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $102 From $91, Reitera..
08/09Wedbush Lifts Price Target on Apellis Pharmaceuticals to $45 From $42, Maintains Neutra..
08/08Apellis Pharmaceuticals Narrows Q2 Loss, Revenue Rises
08/08TRANSCRIPT : Apellis Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 08, 2022
08/08Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Revenue $16.3M
08/08Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Loss $-1.46
08/08Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
08/08APELLIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 81,3 M - -
Net income 2022 -621 M - -
Net cash 2022 229 M - -
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 7 465 M 7 465 M -
EV / Sales 2022 89,1x
EV / Sales 2023 27,1x
Nbr of Employees 476
Free-Float 83,5%
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 18
Last Close Price 67,95 $
Average target price 74,71 $
Spread / Average Target 9,94%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors